April 29 (Reuters) - Perspective Therapeutics Inc CATX.A:
PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH PSV359 IN A PHASE 1/2A STUDY IN PATIENTS WITH FAP-Α POSITIVE SOLID TUMORS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.